Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022

Figures & data

Figure 1. Flowchart of the literature searching and screening in the study.

Figure 2. Global trend of publications and meanTCperyear of citations on RCC immunotherapy from 2003 to 2022.

Figure 3. (a) Geographic distribution map based on the total publications of different countries/regions. (b) Co-authorship between countries. (c) Co-authorship between institutions.

Table 1. Top 10 co-authorship: countries, institutions, and authors.

	Country	records	Insititution	records	Author	records
1	USA	1864	Harvard University	264	Choueiri, Toni K	55
2	PEOPLE RCHINA	815	University of Texas System	247	Mcdermott, David F	49
3	ITALY	497	UDICE-French Research Universities	233	Santoni, Matteo	47
4	GERMANY	482	UNICANCER	191	Massari, Francesco	45
5	FRANCE	390	University of California System	190	Porta, Camillo	36
6	JAPAN	318	UTMD Anderson Cancer Center	178	Pal, Sumanta K	33
7	ENGLAND	270	Assistance Publique Hopitaux Paris (APHP)	149	Albiges, Laurence	32
8	SPAIN	197	Dana-Farber Cancer Institute	143	Buti, Sebastiano	30
9	CANADA	192	Institut National de la Sante et de la Recherche Medicale (Inserm)	139	Rini, Brian I	29
10	NETHERLANDS	159	Harvard Medical School	134	Procopio, Giuseppe	27

Table 2. The top 10 countries with high centrality value.

	Country	Centrality
1	JORDAN	1.09
2	CZECH REPUBLIC	0.94
3	SERBIA	0.8
4	RUSSIA	0.61
5	FINLAND	0.36
6	SAUDI ARABIA	0.35
7	LITHUANIA	0.34
8	SLOVENIA	0.33
9	BELGIUM	0.31
10	NETHERLANDS	0.3

Table 3. Top 10 references with highest citations.

	References	Citations	First author	Year	Journal
1	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma	589	Motzer RJ	2018	NEW ENGL J MED
2	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma	527	Motzer RJ	2015	NEW ENGL J MED
3	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma	454	Rini BI	2019	NEW ENGL J MED
4	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinomar	381	Motzer RJ	2019	NEW ENGL J MED
5	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer	238	Topalian SL	2012	NEW ENGL J MED
6	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma	223	Motzer RJ	2007	NEW ENGL J MED
7	Sorafenib in advanced clear-cell renal-cell carcinoma	200	Escudier B	2007	NEW ENGL J MED
8	Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	180	Siegel RL	2018	CA-CANCER J CLIN
9	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomized controlled trial	179	Rini BI	2019	LANCET
10	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma	177	McDermott DF	2018	NAT MED

Figure 4. (a) A timeline view for co-cited references associated with RCC immunotherapy. (color version of figure is available online.) (b) CiteSpace visualization map of top 25 references with the strongest citation bursts from 2003 to 2022.

Table 4. Top 10 journals and authors with highest citations.

	Journal	Records	Author	Records
1	J CLIN ONCOL	3350	MOTZER RJ	2087
2	NEW ENGL J MED	3337	RINI BI	1155
3	CLIN CANCER RES	2903	ESCUDIER B	974
4	CANCER RES	2478	CHOUEIRI TK	874
5	LANCET	1961	MCDERMOTT DF	713
6	ANN ONCOL	1942	ROSENBERG SA	588
7	NATURE	1795	TOPALIAN SL	568
8	LANCET ONCOL	1760	SIEGEL RL	559
9	P NATL ACAD SCI USA	1699	YANG JC	539
10	SCIENCE	1643	ATKINS MB	517

Figure 5. (a) Keywords co-occurrence map of publications on RCC immunotherapy. (b) A timeline view for keywords associated with RCC immunotherapy. T (c) CiteSpace visualization map of top 25 keywords with the strongest citation bursts of publications in the field of RCC immunotherapy from 2003 to 2022.

Table 5. Top 20 keywords in terms of records.

	Keywords	Records	Keywords	Centrality
1	renal cell carcinoma	1585	interferon alpha	1.33
2	immunotherapy	963	chemotherapy	0.71
3	expression	617	endothelial growth factor	0.65
4	survival	615	renal cell carcinoma	0.64
5	interferon alpha	557	combination	0.63
6	sunitinib	485	5 fluorouracil	0.63
7	nivolumab	391	activated killer cells	0.58
8	t cells	368	patients pts	0.57
9	targeted therapy	338	phase ii trial	0.56
10	dendritic cells	307	Multicenter	0.44
11	interleukin 2	261	targeted therapy	0.42
12	Immune checkpoint inhibitors	226	ipilimumab	0.42
13	ipilimumab	218	dendritic cells	0.4
14	regulatory t cells	208	Tumor infiltrating lymphocytes	0.38
15	everolimus	204	cytoreductive nephrectomy	0.37
16	endothelial growth factor	198	phase ii	0.35
17	cancer immunotherapy	196	immunotherapy	0.34
18	tumor microenvironment	193	pembrolizumab	0.33
19	blockade	189	subcutaneous interleukin 2	0.32
20	chemotherapy	188	dose interleukin 2	0.26
21	phase ii trial	178	vaccination	0.25
22	combination	173	interferon alpha 2a	0.24
23	efficacy	166	randomized trial	0.23
24	safety	165	cytotoxic t lymphocytes	0.23
25	pembrolizumab	162	autologous tumor	0.23

Data availability statement

The original data supporting the conclusion of this article will be provided by the author without any reservations.